Modulation of cutaneous inflammation by angiotensin-converting enzyme

被引:64
作者
Scholzen, TE [1 ]
Ständer, S [1 ]
Riemann, H [1 ]
Brzoska, T [1 ]
Luger, TA [1 ]
机构
[1] Univ Munster, Ludwig Boltzmann Inst Cell & Immunobiol Skin, Dept Dermatol, D-48149 Munster, Germany
关键词
D O I
10.4049/jimmunol.170.7.3866
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cutaneous neurogenic inflammation is a complex biological response of the host immune system to noxious stimuli. Present evidence suggests that zinc metalloproteases may play an important role in the regulation of neurogenic inflammation by controlling the local availability of neuropeptides, such as substance P (SP), that are capable of initiating or amplifying cutaneous inflammation after release from sensory nerves. To address the hypothesis that the dipeptidyl carboxypeptidase angiotensin-converting enzyme (ACE) is capable of modulating skin inflammation, we have analyzed murine allergic contact dermatitis (ACD) and irritant contact dermatitis (ICD) using wild-type C57BL/6J (ACE(+/+)) or genetically engineered mice with a heterozygous deletion of somatic ACE (ACE(+/-)). In 2,4-dinitro-1-fluorobenzene-sensitized ACE(+/-) mice, ACD was significantly augmented in comparison to ACE(+/+) controls as determined by the degree of ear swelling after exposure to hapten. Likewise, systemic treatment of ACE(+/+) mice with the ACE inhibitor captopril before sensitization or elicitation of ACD significantly augmented the ACD response. In contrast, local damage and neuropeptide depletion of sensory nerves following capsaicin, injection of a bradykinin B-2, or a SP receptor antagonist before sensitization significantly inhibited the augmented effector phase of ACD in mice with functionally absent ACE. However, in contrast to ACD, the response to the irritant croton oil was not significantly altered in ACE(+/-) compared with ACE(+/+) mice. Thus, ACE by degrading bradykinin and SP significantly controls cutaneous inflammatory responses to allergens but not to irritants, which may explain the frequently observed exacerbation of inflammatory skin disease in patients under medication with ACE inhibitors.
引用
收藏
页码:3866 / 3873
页数:8
相关论文
共 66 条
[11]   ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS AS POSSIBLE EXACERBATING DRUGS IN PSORIASIS [J].
GILLEAUDEAU, P ;
VALLAT, VP ;
CARTER, DM ;
GOTTLIEB, AB .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1993, 28 (03) :490-492
[12]   SUBSTANCE-P AND CALCITONIN-GENE-RELATED PEPTIDE MODULATE LEUKOCYTE INFILTRATION TO MOUSE SKIN DURING ALLERGIC CONTACT-DERMATITIS [J].
GOEBELER, M ;
HENSELEIT, U ;
ROTH, J ;
SORG, C .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1994, 286 (06) :341-346
[13]  
Grabbe S, 1996, Am J Contact Dermat, V7, P238, DOI 10.1016/S1046-199X(96)90057-3
[14]   Dissection of antigenic and irritative effects of epicutaneously applied haptens in mice - Evidence that not the antigenic component but nonspecific proinflammatory effects of haptens determine the concentration-dependent elicitation of allergic contact dermatitis [J].
Grabbe, S ;
Steinert, M ;
Mahnke, K ;
Schwarz, A ;
Luger, TA ;
Schwarz, T .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (05) :1158-1164
[15]  
Grabbe S, 1996, J IMMUNOL, V156, P473
[16]   IL-12 acts directly on DC to promote nuclear localization of NF-κB and primes DC for IL-12 production [J].
Grohmann, U ;
Belladonna, ML ;
Bianchi, R ;
Orabona, C ;
Ayroldi, E ;
Fioretti, MC ;
Puccetti, P .
IMMUNITY, 1998, 9 (03) :315-323
[17]   NEUROPEPTIDES ENHANCE IRRITANT AND ALLERGIC CONTACT-DERMATITIS [J].
GUTWALD, J ;
GOEBELER, M ;
SORG, C .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1991, 96 (05) :695-698
[18]   Angiotensin-converting enzyme and male fertility [J].
Hagaman, JR ;
Moyer, JS ;
Bachman, ES ;
Sibony, M ;
Magyar, PL ;
Welch, JE ;
Smithies, O ;
Krege, JH ;
O'Brien, DA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (05) :2552-2557
[19]   BRADYKININ RECEPTORS - PHARMACOLOGICAL PROPERTIES AND BIOLOGICAL ROLES [J].
HALL, JM .
PHARMACOLOGY & THERAPEUTICS, 1992, 56 (02) :131-190
[20]  
Ho WZ, 1997, J IMMUNOL, V159, P5654